Difference between revisions of "Resource:C1141bae-df2e-4f56-85aa-7e26dc38197b"

From The Embassy of Good Science
 
Line 2: Line 2:
 
|Resource Type=Cases
 
|Resource Type=Cases
 
|Title=Clinical Trials and Drug Promotion: Selective Reporting of Study 329
 
|Title=Clinical Trials and Drug Promotion: Selective Reporting of Study 329
|Is About=This article describes the ethical issues regarding the Study 329. The Study wanted to determine the efficacy and safety of imipramine and paroxetine in the treatment of adolescents with major depression. However, it did not comply with the study protocol and ignored important safety problems, which led to some harmful effects.
+
|Is About=This article describes ethical issues regarding the Study 329. The Study wanted to determine the efficacy and safety of imipramine and paroxetine in the treatment of adolescents with major depression. However, it did not comply with the study protocol and ignored important safety problems, which led to some harmful effects.
 
|Important For=Researchers; Educators; Policy makers
 
|Important For=Researchers; Educators; Policy makers
 
}}
 
}}

Latest revision as of 12:56, 2 September 2021

Cases

Clinical Trials and Drug Promotion: Selective Reporting of Study 329

What is this about?

This article describes ethical issues regarding the Study 329. The Study wanted to determine the efficacy and safety of imipramine and paroxetine in the treatment of adolescents with major depression. However, it did not comply with the study protocol and ignored important safety problems, which led to some harmful effects.

For whom is this important?

Other information

Cookies help us deliver our services. By using our services, you agree to our use of cookies.
5.1.6